- No products in the cart.
RTA (Retatrutide)
Three pathways. One injection.
U.S.-Compounded · 503A Licensed · $35 flat shipping · Discreet
Compounded · GLP-1 Track
What it is
Retatrutide is a triple-receptor agonist — GLP-1, GIP, and glucagon — the next generation of metabolic peptides after semaglutide and tirzepatide. The triple mechanism means appetite regulation, glucose handling, and energy expenditure get addressed at once instead of in sequence. Compounded for us at a U.S. 503A-licensed pharmacy. No imports. No mystery sourcing.
Who this protocol is for
Patients who plateaued on dual-receptor GLP-1s, patients with significant weight to move where the additional glucagon-receptor mechanism matters, and patients working with their medical director on the most aggressive metabolic protocol the compounding space currently supports. Not a starting point — a step beyond.
How the Track works
Weekly subcutaneous injection. Your $149 covers the full year of telehealth — visits, labs, dose adjustments, refills. No per-script fees. Your medical director sets the dose based on your prior GLP-1 exposure, current labs, and goals.
Most patients tell us retatrutide moves the needle when the dual-receptor protocols stop showing them new numbers. The triple mechanism does what its design implies — more leverage at more receptors at once.
Stay on track.